As part of the enrollment process, patient will be assessed through CT scan of the chest/abdomen/pelvis with and without intravenous contrast or with MRI in case of contraindication for iodine contrast, prior to initiate Part B of the treatment (confirming clinically and radiological "no evidence of disease-NED"). Another assessment will be performed 4 weeks after the last dose of 5-azacitidine (to confirm NED status). Patient will be clinically followed up every 3 months until completion of 2 years post-treatment. Imaging tests will be performed every 3 months with CT scan as part of the standard follow-up until completion of 2 years post-surgery. After 2 years of post-treatment completion, patient will be followed up every 6 months in the clinic and also by radiographic studies until completion of 5 years post-treatment. In the case of clinical suspicion for progression, patient will undergo a thorough and complete work-up to rule out this possibility. This may include imaging diagnostic tests, biopsy, or other tests and procedures.